ライフサイエンスコーパス: progestin therapy

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します

1 d endometrial cancers that do not respond to progestin therapy.

2 breast cancer risk from menopausal estrogen-progestin therapy.

3 ERS) was a randomized trial of estrogen plus progestin therapy after menopause.

4 Estrogen plus progestin therapy among postmenopausal women with known

5 vestigate the relation between estrogen plus progestin therapy and risk of stroke among postmenopausa

6 udies now show that combination estrogen and progestin therapy appears to also result in a reduction

7 Estrogen and progestin therapy appears to have a more favorable effec

8 gnificant effect of 4 years of estrogen plus progestin therapy compared with placebo on knee pain and

9 In addition, estrogen plus progestin therapy did not prevent mild cognitive impairm

10 HIMS) previously reported that estrogen plus progestin therapy does not protect cognition among women

11 Postmenopausal estrogen and progestin therapy (EPT) increases mammographic percent d

12 prospective trial of combined estrogen plus progestin therapy for disease prevention.

13 with progestins may improve the efficacy of progestin therapy for the treatment of endometrial cance

14 benefit of estrogen therapy and estrogen and progestin therapy in observational studies of postmenopa

15 ls have examined the effect of estrogen plus progestin therapy in postmenopausal women on the risk fo

16 On July 8, 2002, the estrogen plus progestin therapy in the WHI trial was discontinued beca

17 Estrogen plus progestin therapy increased the risk for probable dement

18 Estrogen plus progestin therapy increased the risks associated with ag

19 Estrogen plus progestin therapy increases the risk for coronary heart

20 Response to progestin therapy is more frequent among patients with a

21 gests that continuous combined estrogen plus progestin therapy may increase the risk of ovarian cance

22 clerosis and the extent to which concomitant progestin therapy may modify these effects.

23 r, about the effect of combined estrogen and progestin therapy on the risk of cardiovascular disease.

24 3.93, 95% CI: 1.43, 10.84), or estrogen-plus-progestin therapy (OR = 3.51, 95% CI: 1.45, 8.49).

25 It showed that estrogen plus progestin therapy reduced fractures (46 fewer per 10 000

26 Conjugated estrogen, alone or combined with progestin therapy, reduced PAI-1 levels by approximately

27 In postmenopausal estrogen progestin therapy users, carriers of the less active AR-

28 eats predicts breast cancer risk in estrogen progestin therapy users.

29 rial cancers; however, the response rates to progestin therapy vary and the molecular mechanisms behi

30 individual and combined effects of estrogen/progestin therapy versus lovastatin on lipids and flow-m

31 rd ratio for continuous use of estrogen plus progestin therapy was 2.36 (95% CI, 1.55 to 3.62) for th

32 Use of estrogen-plus-progestin therapy was not associated with the risk of pa

33 endometrioid tumors were found with estrogen/progestin therapy, whereas no association was found with

34 n's Health Initiative trial of estrogen-plus-progestin therapy, women assigned to active treatment ha

WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。